We derive the closed-form restricted maximum likelihood (REML) estimator and Kenward-Roger's variance estimator for fixed effects in the mixed effects model for repeated measures (MMRM) when the missing data pattern is monotone. As an important application of the analytic result, we present the formula for calculating the power of treatment comparison using the Wald t test with the Kenward-Roger adjusted variance estimate in MMRM. It allows adjustment for baseline covariates without the need to specify the covariate distribution in randomized trials. A simple two-step procedure is proposed to determine the sample size needed to achieve the targeted power. The proposed method performs well for both normal and moderately nonnormal data even in small samples (n = 20) in simulations. An anti-depressant trial is analyzed for illustrative purposes.
Introduction
In clinical trials, the mixed effects model for repeated measures (MMRM) is commonly used to analyze longitudinal continuous outcomes collected at a number of fixed time points [1, 2, 3] . In MMRM, there is no random effect, and the within-subject dependence is modeled by an unstructured covariance matrix. It assumes that the post-baseline outcome y i = (y i1 , . . . , y ip )
′ follows a p-dimensional multivariate normal distribution
where x i is the baseline covariate (including intercept and treatment status) for subject i, and α j is the q × 1 vector of covariate and treatment effects at visit j. In clinical trials, the primary analysis model is generally pre-specified in the protocol. While it is difficult, if not impossible, to correctly pre-specify the covariance structure, the use of an unstructured covariance matrix usually provides reasonable control of the type I error rate [1] . Any stronger assumptions on the mean response or covariance structure can be difficult to be accepted by regulatory agencies without rigid justifications. The restricted likelihood is the marginal likelihood of KY , where N = n i=1 r i and K is any (N − pq) × N matrix of full rank satisfying KW = 0. The restricted log-likelihood ℓ r does not depend on α and the choice of K, and can be expressed as [14, 15] 
where Σ k is the leading k × k submatrix of Σ. ′ are the regression parameters of y ij on y j−1 = (y i1 , . . . , y i,j−1 ) ′ since model (1) can be written as
which can be reorganized as [9] 
where y ij = y ij − j−1 t=1 β jt y it , α j = α j − j−1 t=1 β jt α t , θ j = (α (4) is given bŷ θ j,ml =θ j andσ 2 j,ml =Ŝ j /n j .
Lemma 1 derives the closed-form REML estimator for the parameters in model (1) . Its proof is given in the appendix.
Lemma 1 (a) The asymptotic variance of the fixed effect estimate
, where I q is the q × q identity matrix, and
(b) The restricted log-likelihood (2) can be decomposed as the sum of p independent log-likelihoods ℓ r = p j=1 ℓ rj + constant, where 
Remarks: 1) Lemma 1(a) is also valid for models with structured covariance matrix; 2) We set
Lemma 1(b) can also be derived from the Bayesian viewpoint based on the fact [14] that the restricted likelihood is proportional to the marginal posterior density over the variance parameters under a flat prior for (α, Σ). We have to ignore the Jacobian correction factor in the posterior density under reparameterization since the REML estimators are invariant under reparameterization. Under a flat prior, (θ j , σ 2 j )'s are independent in the posterior distribution, and the posterior density of (θ j , σ 2 j ) is proportional to the likelihood function for model (4) , which implies that
The marginal posterior distribution of (β j , σ 2 j ) is given by
Bias in parameter estimates
The LS, ML and REML methods produce identical estimate of θ j 's. Sinceθ j is an unbiased estimate of θ j , it is easy to show by induction that (l j1 , . . . ,l jj ) andα j = j t=1l jtα t are unbiased respectively for (l j1 , . . . , l jj ) and
The bias is not invariant to reparameterization. In REML, the bias inΣ =LΛL ′ is of the order of O(n −2 ). It can be derived by the Cox-Snell [16] method (using the equation on line 21, page 2586 of [17] and equation (9.62) of [18] ), or based on the second-order Taylor series expansion ofΣ
Variance of fixed effects
The fixed effect estimate isα 
In the appendix, we show cov(α p −α p ,α p ) = 0, and derive the variance ofα p −α p 
Although Ψ p is of lower order than Φ p , it is not negligible in small samples. The variance at other visits can be derived similarly, and would not be presented here.
i∈Bgs (x bi −x gs ) ⊗2 and V xs = n −1
xs ∆ s , where a ⊗2 = aa ′ . By equation (7), the variance of the treatment effect estimateτ p is given by
Kenward-Roger (KR) variance estimate
The KR variance estimate has been widely used in practice particularly when the sample size is small. The KR approach not only takes into account of the variability in the variance parameter estimate, but also adjusts for the bias inΦ p . In the appendix, we show the bias inΦ p is
If var E (β j ) in Lemma 1d is used, then ω jt σ
, and Ψ * p = −Ψ p . The KR variance evaluated at the REML estimator is given by
and it provides a roughly unbiased estimate of the variance Φ p + Ψ p ofα p while the lower order terms are dropped. The KR variance estimate is invariant under reparameterization of an unstructured covariance matrix [17] . Although the derivation of the KR variance estimate relies on var E (β j ), equation (10) yields the same result as Kenward-Roger's [10] formula if the calculation is based on var O (β j ).
Delta variance estimate
An alternative variance estimate forα p can be obtained from the delta method
where ∂α p /∂θ j = l pjαj andα j = (I q , α 1 , . . . , α j−1 ). By equation (19) in the appendix, the delta variance evaluated at the LS estimator can be written aŝ 
The delta variance is closely related to the variance from the multiple imputation (MI) inference [19] . One may compare the KR variance estimate given in equation (10) with the MI variance derived by [19] . In general, the MI inference tends to be slightly more conservative than the REML inference [2].
Analysis of an antidepressant trial
To illustrate the analytic result derived in this section, we analyze an antidepressant trial reported by [11] . The Hamilton 17-item rating scale for depression (HAMD 17 ) is collected at baseline and weeks 1, 2, 4, 6. The dataset consists of 84 subjects on the active treatment, and 88 subjects on placebo. The number of subjects in patterns 0 to 4 is respectively (0, 7, 5, 11, 65) in the placebo arm, and (0, 6, 5, 9, 64) in the active arm. The missing data are mainly due to dropout. Only one subject has an intermittent missing value at visit 2. We impute the intermittent missing value as 11.70432 based on the linear regression of y i2 on (y i0 , y i1 , g i ), where y i0 is the baseline HAMD 17 . A better approach would be to replace the missing value with multiple plausible values to reflect uncertainty about the missing data via the MI procedure [20, 9] . However, due to the small amount of non-monotone missing data, the result from this single imputation approach is very close to that from the MI inference [20] . Table 1 reports the result from the MMRM analysis. The model includes visit, baseline × visit and treatment × visit interactions as the fixed effects, and an unstructured covariance matrix is used to model the within-patient errors. This corresponds to
′ in terms of model (1) . SAS PROC MIXED yields the same result as our analytic formulae if a more stringent convergence criterion (CONVG= 1E-10 option) than the default is used. The KR variance estimate is smaller than the delta variance, but slightly larger than the asymptotic variance. The p-value for testing the treatment effect at week 6 is 0.0132 based on the KR variance estimate. Table 1 also reports the result from the constrained longitudinal data analysis (cLDA), in which the baseline outcome is treated as a response variable instead of a covariate, and constrained to have equal mean across treatment groups [21, 22] . For monotone missing pattern, the REML estimate and the associated variance estimate can be derived using essentially the same technique described in Sections 2.1 and 2.3, and the details are omitted here. The REML estimates are in fact identical, and the corresponding KR variance estimates are very close in MMRM and cLDA. This is consistent with the simulation result reported in [22] . The cLDA is useful if there is a non-negligible amount of missing data at baseline. However, for monotone missing data, the MMRM is generally preferred since there is no need to assume that y i0 's are normally distributed and that the baseline means are equal across treatment groups in MMRM.
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Power and sample size formulae
Throughout Section 3, we assume the hypothesis of interest is to test the treatment effect at the last visit. Let γ g be the proportion of subjects randomized to group g, π gt the retention rate at visit t in group g, andπ t = 1 g=0 γ g π gt the pooled retention rate at visit t. Then n gt = nγ g π gt . In the variance expression (8), x bi 's are assumed to be fixed in the analysis, but unknown at the design stage. We will replace V xj 's in equation (8) by their expected values. Suppose the covariates are balanced between two arms. We don't require the covariates to be continuous, or follow a specific distribution in randomized trials. Let q * be the dimension of x bi , q = q * + 2 and
xt ∆ t approximately follows a F distribution with q * and n t − q * − 1 d.f. (this holds exactly if x bi is normally distributed). We have
where
If we use var
The power of the Wald test at a two-sided significance level of α is given by
where var kr (τ p ) is the (q, q) entry of var kr (α p ) defined in equation (10), λ = τ p / ̟ τ (n), t(f, ν) is distributed as a non-central t distribution with f d.f. and non-central parameter ν, and t f,p is the p-th percentile of t f . To simplify the calculation, we approximate the power by
approximately follows a t distribution with f d.f., and
For a scalar fixed effect, Kenward and Roger [10] used the Satterthwaite-type d.f., which is a random variable (could be larger than n 1 − q), and difficult to evaluate at the design stage. We approximate f by
can be roughly interpreted as the fraction of observed information among subjects retained at visit 1.
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There is no closed-form solution for the sample size needed to achieve a desired power P . We propose a two-step procedure to approximate the required size. Inverting equation (13) yields
In large samples, we can approximate t f,p by the pth percentile z p of N (0, 1), and approximate
In step 1, we find the sample size based on the normal approximation
and it generally provides a sharp lower bound on the required size. If the retention rate is low (e.g.π p < 0.5), we use the first equality in equation (15) . In the implementation, we round n l up to the nearest integer. In step 2, we use the approximation
and it usually provides a very good estimate of the required size. We may approximate n u by
We recommend using equation (16) or equation (17) to estimate the sample size, and using equation (12) to evaluate the nominal power at a given sample size since equation (12) is more accurate than equation (13) when f is extremely small (e.g. f < 12). If the nominal power at n u or n * u is not close to the targeted power, one may increase or decrease the sample size to achieve the desired power.
We also try a slight variation of the proposed size estimation procedure by increasing n l defined in equation (15) by 2, but all other steps remain the same. More details are provided in simulation 1 reported in Section 3.2.1 below.
Numerical examples

Simulation 1.
In an antidepressant trial analyzed in Section 2.4, the active treatment is significantly better than placebo in reducing depression. It might be of interest to design a new study to assess the effect of a similar compound on HAMD 17 . Suppose p = 4, y i0 
and the retention rate is (π 01 , . . . , π 04 ) = (1, 0.92, 0.86, 0.74) and (π 11 , . . . , π 14 ) = (1, 0.93, 0.87, 0.76). These parameters are specified based roughly on the MMRM analysis of the antidepressant trial. Note that the sample size depends on the retention rates, the treatment effect τ 4 at the last visit, and Σ. Other parameters are specified in order to simulate the data. For the purpose of illustration, we set τ 4 = −4, −8 or −12, and three alternative covariance structures are also considered: 1) a compound symmetry (CS) structure: Σ kk = 45 and Σ kj = 15 if k = j; 2) an autoregressive (AR(1)) structure Σ jk = 45 × 0.8 |j−k| ; 3) a Toeplitz structure Σ jk = 40 − 6|j − k|. For CS and AR(1) structures, the analytic Y. Tang   Statistics  in Medicine   Table 2 : Calculated sample sizes and simulated power based on 10, 000 replications for testing H 0 : τ 4 = 0 in simulation 1: a The sample size is evaluated using equation (16) . The size estimates from equations (15) and (17) are presented for the purpose of comparison;
b The difference in sample size between two arms is 0 for even n and 1 for odd n;
c The nominal power is evaluated as Pr(t(f (n), √ n|τ 4 |/ ̟ τ (n l )) ≥ t f (n),0.975 ) based on equation (12) . The difference in nominal power estimated by equation (12) and equation (13) expressions for the LDL decomposition provided in the appendix can be used in the calculation. We calculate the sample size necessary to achieve 90% power at a two-sided significance level of α = 0.05 using equation (16) . In each case, 10000 datasets are simulated and analyzed using model (1) and KR variance estimate. There is about 95% chance that the simulated power lies within 0.6% (standard error ≈ 0.9 * 0.1/10000 = 0.3%) of the true power. The result is summarized in Table 2 . The difference between the simulated and nominal power is < 1% in all cases.
Empirical evidence indicates that the normal approximation based on equation (15) usually underestimates the sample size by at least 2. We try a slight variation of the sample size estimation procedure by increasing n l by 2 (all other steps remain the same). This modification makes a difference mainly in small samples (i.e. τ 4 = −12) in that the sample size estimate is reduced by 1. We still recommend the procedure described in Section 3.1 since it is generally desirable to use a conservative size estimate.
Simulation 2.
This simulation illustrates that the power and sample size depend on the number of covariates. The covariates consist of the baseline outcome y i0 , treatment status g i and a categorical prognostic factor A with three levels. Suppose the status of the prognostic factor is A i for subject i, y i0
2 ), and
where η 1 = 0, η 2 = −0.5, η 3 = 0.5, and µ ij 's are defined in simulation 1. We assume that the effect of the prognostic factor is constant over time, and that each subject is in level 1, 2 and 3 of the prognostic factor with probability 0.3, 0.4, and 0.3 respectively. Other assumptions are the same as that in simulation 1. In the MMRM analysis, the fixed effects include visit, y i0 × visit, A × visit and treatment × visit interactions. The result is displayed in Table 3 . The required size in simulation 2 is larger than that in simulation 1 under the same assumption on the treatment effect and residual covariance matrix Σ due to the increase in the number of baseline Statistics in Medicine Y. Tang   Table 3 : Calculated sample sizes and simulated power based on 10, 000 replications for testing H 0 : τ 4 = 0 in simulation 2:
a The sample size is evaluated using equation (16) . The size estimates from equations (15) and (17) are presented for the purpose of comparison;
c The nominal power is evaluated as Pr(t(f (n), covariates. The difference between the simulated and nominal power is < 1% in all cases. Overall, the sample size is underestimated by the normal approximation approach given in equation (15) especially at τ 4 = −12, and the proposed two-step sample size calculation method performs well when the d.f. in equation (16) is larger than f (n l ) ≥ 12.
Simulation 3.
So far, we assume the data are normally distributed. The third simulation is conducted to assess the performance of the proposed method for non-normal data in small to moderate samples (τ 4 = −8 or −12). The data are simulated from the multivariate skew-normal distribution [23] and multivariate t distribution. For the purpose of comparison, we set the covariance matrix of (y i1 , . . . , y i4 ) and the treatment effect at each visit to be identical to that in simulation 1. The nominal power and sample size estimates will be same as that in simulation 1. In the multivariate t distribution, we generate the data as The skew-normal distribution [23] can be used to model data that are mildly to moderately skewed. Let
be the correlation matrix corresponding to Σ, and
, where κ is a prespecified scalar value in the interval (−1, 1) ,
The data are generated as
The covariance matrix of (y i1 , . . . , y i4 ) ′ is Σ. The marginal distribution ofǫ ij is N (0, 1), and the skewness of ǫ ij (y ij has the same skewness as ǫ ij ) ranges from −0.995 to 0.995 as κ changes from −1 to 1. We set κ = 0.8 and 0.9. No result is produced for the CS covariance structure at κ = 0.9 since the corresponding R 2 is not positive definite. The result is presented in Table 4 . In general, the type I error is close to the nominal 5% level except in few cases under the t distribution with 6 d.f., where the t test with KR adjusted variance provides slightly conservative control of the type I error. The performance on the power estimate is almost as good as that under the normality assumption in simulation 1. The simulated power is within 1.2% of the nominal power in all cases. Additional simulation (results not shown) is conducted under the skew-normal distribution at κ = −0.8, −0.9 and ±0.95, and different covariance matrices may be used to ensure that R 2 is positive definite. All simulations indicate that the proposed power and sample size estimation procedure is fairly robust to mild or moderate deviations from non-normality even when n = 20.
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Statistics in Medicine Table 4 : Calculated sample sizes and simulated power based on 10, 000 replications for testing H 0 : τ 4 = 0 under multivariate t and skew-normal distributions in simulation 3:
a The sample size and nominal power estimates are identical to that in simulation 1;
b Type I error (Type1) is evaluated at τ 4 = 0; c Simulated power (SIM) is evaluated at τ 4 = −8 and −12.
total nominal skew-normal distribution (%) multivariate t distribution (%) true covariance size 
Discussion
We derive the closed-form REML estimator and compare several variance estimators for fixed effects in MMRM when the missing data pattern is monotone. The bias in the ML and REML parameter estimators is assessed. For monotone missing data, the MMRM yields the same treatment effect as the cLDA [22] , but it makes less assumption on the distribution of baseline outcomes. One referee raises concern over the terminology MMRM since there is no random effect in model (1) . We partially agree with the referee, but this terminology is commonly used in the pharmaceutical industry [1, 2, 3] . A two-step sample size determination procedure is proposed for the KR adjusted t test for comparing two treatments in MMRM. Simulation demonstrates its good performance even in small samples. When the d.f. given in equation (16) is f (n l ) < 12, the power formula (12) still works reasonably well, but the required size can be overestimated. The main reason is because the normal approximation approach generally underestimates the required size and hence the d.f., leading to non-negligible inflation in t f,1−α/2 + t f,P and ̟ τ (n) in small samples. When f (n l ) < 12, we would recommend using a numerical (e.g. bisection) method to find the size based on equation (12), which is the smallest integer at which the power reaches the pre-specified level. Simulation indicates that the proposed method is quite robust to mild or moderate deviations from non-normality. However, this robustness property may not hold under severe non-normality even for the one sample t test [24] . It is always prudent to run a simulation study to verify the power and sample size estimate especially when the data are highly non-normal or when the sample size is small. We assume balanced baselines across groups. If the baselines are imbalanced, we may replace equation (11) by
where µ d is the difference in mean of x bi between two arms, Σ x is the covariance matrix of x bi and D = µ
In a companion paper, we investigate the power of treatment comparison in an unstratified randomized trial, and the power for testing treatment effect and treatment by stratum interaction in a stratified trial using analysis of covariance (ANCOVA). For the MMRM analysis of a stratified trial with h strata, we may replace equation (11) by
where q * is the dimension of covariates excluding intercept, treatment status, and pre-stratification factors, (x i1 , . . . ,
are the indicator variables for strata,
and q = q * + h + 1. Equation (18) (12) and (13) and the last term in equations (15) and (16) can greatly improve the accuracy of the power and sample size estimate when q * is large or n is relatively small. Covariate selection is critical in small trials. In the power calculation, Σ = LΛL ′ is the variance of the outcome unexplained by the covariates. Inclusion of important covariates can reduce the residual variance Σ, and increase the power of the analysis. However, if the covariates are unrelated or only weakly related to the outcome, both the precision of the treatment effect estimate (by equation (11)) and the d.f. in the t test may decrease, resulting in reduced power. It can be challenging to specify Σ at the design stage of a trial. One strategy is to assume a structured covariance matrix that represents the best guess about the true covariance matrix to reduce the number of nuisance parameters in the sample size calculation [12] , but the data are still analyzed by model (1) . Furthermore, blinded size reassessment procedure may be used to re-estimate the variance parameters and adjust the size based on interim blinded data, in which the treatment effect is generally small and thus ignored in estimating the variance parameters [25] .
We assume monotone missing pattern in the power and sample size calculation. In practice, the trials generally contain only a small amount of intermittent missing data. For example, in the anti-depressant trial analyzed in Section 2.4, only one out of 172 subjects has intermittent missing values. In the presence of non-monotone missing data, sample size can be calculated in a slightly conservative way by excluding subjects with intermittent missing data or by excluding data collected after the first missing visit. One needs to adjust the retention rates before applying the power and sample size formulae derived in section 3.1. If a large amount of intermittent missing data is expected, one may use simulation to find the appropriate sample size. The above approach provides an upper size bound, and a lower size bound can be obtained by pretending there are no intermittent missing data.
One limitation of the proposed method is that the data are assumed to be missing at random in the MMRM. Sensitivity analyses under the nonignorable missingness have become increasingly popular in new drug applications [26, 20, 9] . Sample size formulae for such sensitivity analysis may be obtained by using the analytical expressions for the MI treatment effect estimate and the associated variance derived in [19] .
We have focused on the longitudinal continuous outcome. For other types of longitudinal outcomes (e.g. binary or ordinal), one may use the methods described in [27, 28] to compute the sample size for the tests based on the generalized estimating equations (GEE). However, these methods may not be suitable for small samples [29] .
The analytic REML solution is useful in statistical computing. For example, we find the default REML estimation algorithm used by SAS Proc mixed fails to converge in about 5% monotone datasets at n = 15 in a simulation, but the REML estimate can be easily obtained using Lemma 1. For near-monotone datasets, the convergence of the REML algorithm may be accelerated by using the REML estimate excluding subjects with intermittent missing data as the initial parameter values. For non-monotone data, Liu [8] proposed a MEM algorithm to find the ML estimate. It is also possible to develop a MEM algorithm for the REML estimation, and the details will be presented elsewhere. (5) yields (β j ,σ 2 j,re )'s, and α j 's are evaluated at the REML estimator (β j ,σ 2 j,re )'s. We can provê θ j,re =θ j by using
where , where V de = diag(0, V d2 + V e2 , . . . , V dp + V ep ).
Proof of equation (9) : Let g j = σ 
